Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study
Following successful PS matching of TLS-risk factors, this study suggests rasburicase statistically significantly reduces TLS-associated mortalities compared to allopurinol.
Authors
- Mitchell Stuart Cairo (ORCID: https://orcid.org/0000-0002-2075-434X)
- Yvonne Barnes
- Jack R. Gallagher (ORCID: https://orcid.org/0000-0002-7026-0022)
- Edward J. Drea
- Susan Carroll (ORCID: https://orcid.org/0000-0002-6456-3318)
Institutions
- Massachusetts Audubon Society (US)
- AVEO Oncology (United States) (US)
- Maria Fareri Children's Hospital (US)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1007/s00520-025-10090-y
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00